CD45+ CECs from the peripheral blood of COVID-19 patients and human bone marrow exhibit the highest intensity of ACE2 expression compared with other immune cells
(A) Plots showing the expression of ACE2 on CD45− CECs versus CD45+ CECs from PBMCs from a COVID-19 patient.
(B) Percentage of ACE2 surface expression on total CECs and immune cell lineages in PBMCs from a COVID-19 patient.
(C) Cumulative data of the percentage of ACE2 expressing cells among different immune cell lineages and CECs in PBMCs from COVID-19 patients.
(D and E) (D) Representative plots and (E) cumulative data of the intensity of ACE2 expression in CD45+ CECs, CD45− CECs, and immune cell lineages measured by mean fluorescence intensity (MFI) in PBMCs from COVID-19 patients.
(F) Representative plots of the percentage of ACEs expression in CD45−, CD45lo, and CD45hiCECs in PBMCs from COVID-19 patients.
(G) Plot showing the intensity of ACE2 expression in CD45hi, CD45lo, and CD45− CECs compared with isotype control in PBMCs from COVID-19 patients.
(H) Plots showing the expression of ACE2 on CD19 B cells, CD3 T cells, CD16CD56 NK cells, CD14 monocytes, and CECs compared with the isotype control antibody in the bone marrow aspirates of a healthy adult.
(I) Representative plots of the percentage of ACEs expression in CD45−, CD45lo, and CD45hiCECs of the bone marrow.
(J) Histogram plot of the intensity of ACE2 expression in CD45hi, CD45lo, and CD45− CECs of the bone marrow compared with isotype control. Each point represents data from one patient. Bar, mean ± 1 standard error.